Collegium PharmaceuticalAktie
 
Mehr Daten anzeigen
Collegium Provides 2021 Financial Guidance

– Xtampza ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million …

Wertpapier:
Collegium Reports Net Income of $11.3 Million in the Third Quarter of 2020

– Strengthened Formulary Access for Xtampza ER, Including Exclusive National Medicare Part D Win – – Generated $34.2 Million in Cash Flow from Operations – – Adjusted EBITDA of $41.8 Million – – Conference Call Scheduled …

Wertpapier:

Nachrichten

ZeitTitel
26.10.20
Collegium Announces Publication of “Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER” in Pain Medicine
22.10.20
Collegium to Host Conference Call to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
30.09.20
Collegium Announces Settlement with Teva Resolving Xtampza ER Patent Litigation
25.09.20
Collegium Appoints Rita Balice-Gordon to its Board of Directors
14.09.20
Collegium Announces Five Posters Presented at PAINWeek 2020 National Conference
09.09.20
Collegium Announces Scientific Presentations at PAINWeek 2020 National Conference
05.08.20
Collegium Reports Net Income of $8.1 Million in the Second Quarter of 2020
21.07.20
Collegium to Host Conference Call to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update
17.06.20
Collegium Pharmaceutical Named one of Boston Business Journal’s 2020 Best Places to Work
07.05.20
Collegium Reports First Quarter 2020 Profitability
23.04.20
Collegium to Host Conference Call to Discuss First Quarter 2020 Financial Results and Provide Corporate Update
07.04.20
Collegium to Participate in Upcoming Investor Conference
27.02.20
Collegium Reports Full-Year 2019 Revenue of $296.7 Million
26.02.20
Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Provide Corporate Update
13.02.20
Collegium Announces Closing of the Nucynta Franchise Acquisition
Diskussionen

Collegium Pharmaceutical Forum

Die wichtigsten Links der Community
Börsenforum - der komplette Überblick
Alle Foren von Anfänger bis Zertifikate
Forum-Suche

Diskussionen

Was halten Sie von den neusten Entwicklungen zu Collegium Pharmaceutical?


Meistdiskutierte Aktien (24h)

WertpapierBeiträge
DAX
250
Sernova
228
Lyxor ETF MSCI World D €
144
Plug Power
132
Gevo
120
Halo Labs
109
Tesla
106
BioNTech
99
NetCents Technology Registered (A)
95
Lang & Schwarz
80